STOCK TITAN

Cytokinetics Announces Presentation at the Virtual 33rd International Symposium on ALS/MND

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Cytokinetics (Nasdaq: CYTK) announced a poster presentation for the FORTITUDE-ALS Phase 2 clinical trial of reldesemtiv, focusing on ALS survival predictions. This session will occur during the Virtual 33rd International Symposium on ALS/MND from December 6-9, 2022. Dr. Tyrell Simkins will present the ENCALS Predictive Survival Model on December 8, 2022, from 5:00-6:30 PM GMT. Cytokinetics specializes in muscle performance therapies and is advancing several clinical candidates, notably omecamtiv mecarbil and aficamten, targeting significant heart conditions and diseases.

Positive
  • Cytokinetics is presenting at a major ALS/MND symposium, enhancing visibility.
  • The company is advancing multiple promising therapies for muscle-related diseases.
Negative
  • No specific positive clinical outcomes or data was mentioned regarding reldesemtiv.

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one poster presentation at the Virtual 33rd International Symposium on ALS/MND taking place online from December 6, 2022 - December 9, 2022 relating to survival predictions from FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints – in ALS), the Phase 2 clinical trial of reldesemtiv in ALS.

Session Title: Live Poster Session C
Presentation Title: ENCALS Predictive Survival Model in FORTITUDE-ALS
Presenter: Tyrell Simkins, Ph.D., Clinical Research Neuromuscular, Cytokinetics
Date: December 8, 2022
Session Time: 5:00-6:30 PM GMT

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is readying for the potential commercialization of omecamtiv mecarbil, its cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is also developing aficamten, a next-in-class cardiac myosin inhibitor, currently the subject of SEQUOIA-HCM, the Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in non-obstructive HCM in Cohort 4 of the Phase 2 clinical trial, REDWOOD-HCM. Cytokinetics is also developing reldesemtiv, an investigational fast skeletal muscle troponin activator, currently the subject of COURAGE-ALS, a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis (ALS). Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the potential benefits of reldesemtiv, including its ability to provide a survival benefit to any person with amyotrophic lateral sclerosis; Cytokinetics’ and its partners’ research and development activities; the timing of enrollment of patients in Cytokinetics’ and its partners’ clinical trials; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics’ drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval; patient enrollment for or conduct of clinical trials may be difficult or delayed; Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ or its partners’ ability to conduct clinical trials; and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Astellas’ decisions with respect to the design, initiation, conduct, timing and continuation of development activities for reldesemtiv; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, including milestones and royalties on future potential product sales under Cytokinetics’ collaboration agreements with such partners. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Communications, Investor Relations
(415) 290-7757


FAQ

What is the focus of Cytokinetics' presentation at the symposium?

Cytokinetics is presenting survival predictions from the FORTITUDE-ALS trial involving reldesemtiv.

When is Cytokinetics presenting at the International Symposium on ALS/MND?

Cytokinetics' presentation is scheduled for December 8, 2022.

What is the significance of the FORTITUDE-ALS trial?

The FORTITUDE-ALS trial evaluates reldesemtiv's impact on survival in ALS patients.

Which clinical candidates is Cytokinetics developing?

Cytokinetics is developing omecamtiv mecarbil, aficamten, and reldesemtiv, among others.

What disorders are Cytokinetics' therapies targeting?

Cytokinetics targets muscle performance disorders, including heart failure and ALS.

Cytokinetics Inc.

NASDAQ:CYTK

CYTK Rankings

CYTK Latest News

CYTK Stock Data

5.73B
115.63M
0.53%
118.71%
12.36%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO